Previous studies demonstrated that a membrane receptor for glucocorticoids (mGR) exists in neuronal membranes from the roughskin newt (Taricha granulosa) and that this receptor appears to be a G protein-coupled receptor (GPCR). The present study investigated the question of whether this mGR recognizes nonsteroid ligands that bind to cognate receptors in the GPCR superfamily. T HERE IS increasing evidence that steroid hormones use multiple signal transduction pathways-the classic genomic pathway, and nongenomic pathways in which membrane receptors are coupled to second messenger systems [for a review see Wehling (1) or Moore and Evans (2)]. Nongenomic pathways are reportedly used by progestins (3, 4), androgens (5), estrogens (6 -8) vitamin D (9), and corticosteroids (10).
T HERE IS increasing evidence that steroid hormones use multiple signal transduction pathways-the classic genomic pathway, and nongenomic pathways in which membrane receptors are coupled to second messenger systems [for a review see Wehling (1) or Moore and Evans (2) ]. Nongenomic pathways are reportedly used by progestins (3, 4) , androgens (5), estrogens (6 -8) vitamin D (9) , and corticosteroids (10) .
An important, and largely unanswered, question concerns the molecular identity of the membrane receptor proteins used by steroid hormones. Recent research, mostly with estrogen and progestins, suggests that steroids use different types of receptors, including enzyme-linked receptors, G protein-coupled receptors, ligand-gated ion channels, or membrane-associated classical steroid receptors. First, one putative estrogen receptor protein is the epidermal growth factor (EGF)-like protein, ErbB2. This protein, when expressed in vitro, binds 17␤-estradiol with high affinity and shows estradiol-induced kinase activity (11) . Similarly, a putative membrane receptor for progesterone is a protein that has structural similarities to enzyme-linked receptors (12) and is localized to endomembranes (13) . This receptor also appears to have a pharmacological profile resembling the sigma receptor (14) . Second, another set of examples indicate that estrogens and progestins can use ligand-gated ion channels. Specific progesterone metabolites (such as 3␣-hydroxy-4-pregnene-20-one) have been found to rapidly modulate the GABA A receptor/chloride channel (15) . Recent studies show that 17␤-estradiol can bind to the ␤ subunit of Maxi-K channels and thereby modulate calcium flux in vascular smooth muscles cells (16) . Third, other studies indicate that intracellular estrogen receptors (ER␣, ER␤) might, in some cases, function as membrane-associated receptors (17). When ER␣ or ER␤ is expressed in cell lines that do not normally contain these receptor proteins, 17␤-estradiol can bind to the membranes and activate the MAP kinase pathways (18). Lastly, there also is evidence that progestins and estrogen use receptor proteins in the GPCR superfamily. For example, 17␤-estradiol modifies GRCR regulated K ϩ channels in guinea pig hypothalamic neurons (8) . Other studies show that progesterone binds to and inhibits the activity of a known GPCR, namely the oxytocin receptor (19). Thus far, the evidence suggests that steroid hormones use multiple types of membrane-associated receptors and, relevant to the current research, that steroids can bind to and modulate known receptors used by other endogenous ligands.
There is considerably less information about the molecular identity of the membrane-associated receptors for corticosteroids, although there is good evidence that corticosteroids regulate various types of rapid responses in different vertebrates. In the cichlid fish Oreochromis mossambicus, cortisol administration to pituitary cells in vitro affects intracellular cAMP and Ca 2ϩ concentrations in lactotrophs within seconds and inhibits PRL secretion within minutes (20). In rats and guinea pigs, neurophysiological studies show that corticosteroid administration decreases Ca 2ϩ currents in specific neurons within a few seconds (21, 22 (43) . Similar suppression of locomotor activity in newts is observed following injection of -selective opioid agonists (44) , whereas this behavior is enhanced by CRH administration (45, 46) . Thus, results from these behavioral studies reveal that corticosterone and -opioid receptor agonists cause similar responses.
The current study investigated the question of whether the high affinity binding site for corticosterone is located on a known GPCR. As a first step toward answering this question, ligand-binding competition studies were run to determine whether any of the peptides or opioid agonists that have been shown to affect newt behaviors (cited above) are recognized by the high affinity binding site for corticosterone in neuronal membranes.
Materials and Methods
All buffers, salts, and drugs were from Sigma (St. Louis, MO) except diprenorphine, bremazocine (BRE), U50,488, and U69,593 were from RBI (Natick, MA); dynorphin (1) (2) (3) (4) (5) (6) (7) (8) (9) (10) (11) (12) (13) 
Preparation of neuronal membranes
Procedures for membrane preparation (P2 membrane pellets) followed the methods of Whittaker (47) Brain tissue was homogenized with a Teflon-on-glass tissue homogenizer. The homogenate was centrifuged at low speed (1,000 ϫ g) for 10 min at 4 C, and the resultant supernatant (S1) was transferred to a clean centrifuge tube. The pellet (P1) was resuspended in homogenization buffer to the original concentration and centrifuged again as above. The pellet was discarded and the supernatant was pooled with S1 and centrifuged at higher speed (30,000 ϫ g) for 40 min at 4 C. The pellet (P2) was quick frozen at Ϫ80 C, then thawed on ice and resuspended in 0.18 ml/mg (original tissue weight) of 25 mm HEPES, 10 mm EDTA, pH 7.45, 100 m PMSF. The suspension of P2 was incubated at 4 C for 2 h to allow the dissociation of any endogenous ligand and centrifuged at 40,000 ϫ g for 15 min. The resultant pellet was washed once by homogenization in 25 mm HEPES, pH 7.45 and recentrifuged at 40,000 ϫ g for 15 min. This final pellet was quick frozen at Ϫ80 C. These well-washed P2 pellets were either stored at Ϫ80 C (for this study less than 3 weeks) or thawed on ice and used immediately. No loss of binding activity has been observed in stored pellets.
Radioligand binding assays
Ligand-binding assays used [ 3 H]CORT and the methods described previously (36). Briefly, membrane preparations (P2 pellets) were suspended in 25 mm HEPES, pH 7.45, 10 mm MgCl 2 at a concentration of 100 g protein (as determined by the method of Lowry, et al. (48) ) per 300 l in each assay tube. Final concentrations were 0.5 nm for [ 3 H]CORT, which approximates the K d value (36), and 10 m for the unlabeled corticosterone that was used to define nonspecific binding. Concentrations for the competitors were as described in Results. Assay tubes were incubated for 4 -6 h at 30 C, conditions that allow binding to reach equilibrium as determined previously in kinetic studies at different temperatures (36, 38). Binding assays were terminated by rapid filtration over GF/C glass fiber filters equilibrated in cold assay buffer. Radioactivity in the filters was counted (cpm) in a Beckman Coulter, Inc. LS 6500 scintillation counter. Radioligand-binding data were analyzed with GraphPad Software, Inc. Prism software.
Results

Initial screen with ligands to G protein-coupled receptors
Ligand-binding competition studies used [ 3 H]CORT with neuronal membranes and GPCR ligands as competitors. Because our objective was to screen as many GPCR ligands as possible for positive effects on displacing [ 3 H]CORT specific binding without using too many animals, each ligand was tested at only one concentration of 10 m. Figure 1 3 H]CORT specific binding was found in assays that included the competitors U69,593 (-specific agonist), nor-BNI (-specific antagonist), diprenorphine (nonselective opioid antagonist), and etorphine (nonselective opioid agonist).
Kinetic analysis for allosteric interactions
Kinetic experiments were performed to evaluate the possibility that the above results might reflect allosteric, rather than direct, interactions between opioid ligands and [ 3 H]CORT binding sites (Fig. 3) . In these experiments, neuronal membranes were incubated with [ 3 H]CORT until equilibrium was reached followed by the induction of dissociation with excess unlabeled corticosterone and/or U50,488. Figure 3 shows that the dissociation curves are similar for U50,488 and corticosterone competitors. Data analysis found that these dissociation curves fit a one-phase exponential decay model with r 2 values of 0.94 for the U50,488 curve and 0.95 for the corticosterone curve. Dissociation rate constants for U50,488 and corticosterone were indistinguishable, with estimated k -1 values of 8.6 ϫ 10 Ϫ3 Ϯ 0.0014 for U50,488 and 9.5 ϫ 10 Ϫ3 Ϯ 0.0017 for CORT. The addition of both competitors (U50,488 plus corticosterone) produced a similar k -1 value 9.0 ϫ 10 Ϫ3 Ϯ 0.0009 and a r 2 value of 0.98. These data are best explained by a single site competition model. as discussed below, support the working hypothesis that the [ 3 H]CORT binding site is located on a opioid-like receptor.
Discussion
Although the current study is the first to find that specific opioid ligands are recognized by a corticosteroid binding site, previous research revealed that other steroids can interact with opioid receptors. Ligand-binding competition studies with neuronal membranes from rats and mice found that the synthetic steroid RU486 decreases specific binding of due to direct competition between corticosterone and these -selective ligands for the same binding pocket. In sum, these studies with mammals and an amphibian suggest that specific steroid hormones might interact with specific types of opioid receptors.
The current study found that the [ 3 H]CORT binding site only recognizes a subset of ligands. The pharmacological profile for the [ 3 H]CORT binding site has similarities to, but is distinctly different from, the mammalian opioid receptor; it recognizes dynorphin, U50,488, BRE, EKC, and naloxone but not U69,593, nor-BNI, diprenorphine, and etorphine. The mammalian opioid receptor binds this entire set of ligands with high affinity. Unfortunately, it is not known whether opioid receptors in T. granulosa have atypical ligand selectivity, because opioid receptors have not been characterized in this species or any other urodele amphibian. Considering studies in frogs, our prediction is that the opioid receptor(s) in T. granulosa are pharmacologically similar to those of mammals. Research in Rana esculenta characterized ligand selectivity for the -binding sites in the brain and found two subtypes of opioid receptors with pharmacological profiles that resemble, but do not exactly match, the KOR1 and KOR2 subtypes in mammals (51, 52) . In frogs and mammals, the defining feature of the KOR1 subtype of opioid receptor is that it recognizes both U50,488 and U69,593, which is interesting because the [ 3 H]CORT binding site in T. granulosa discriminates between these two -specific agonists.
There is evidence that the opioid receptor system developed early in vertebrate evolution (53) . A recent study found that complementary DNA sequences encoding each of the four types of opioid-like receptors [, ␦, , and the orphanin opioid receptor-like receptor (ORL)] occur in representative species of elasmobranchs to mammals (54) . It therefore seems very likely that T. granulosa has these four types of opioid receptors as well. In mammals there are multiple subtypes of the ␦, , and ORL receptors, some of which are derived from stable splice variants with tissue-specific distribution (55, 56) . None of these subtypes in mammals have been specifically characterized pharmacologically or linked to specific physiological functions. The presence of these multiple subtypes exposes the possibility that one of the subtypes could function as a membrane corticosteroid receptor.
Our earlier behavioral studies in T. granulosa are consistent with the working hypothesis that the [ 3 H]CORT binding site is located on a opioid-like receptor. Those studies found   FIG. 3 . Kinetic analysis of dissociation rates. Binding assays were set up as described in the methods section and allowed to equilibrate for 6 h before adding competitors. Both U-50,488 and CORT competitors were added to achieve final concentrations of 10 M. Dissociation time points were initiated in an inverse order and assays were terminated simultaneously by rapid filtration as described in Materials and Methods. Data were analyzed with GraphPad Software, Inc. Prism software using a one phase exponential decay to determine k -1 values. Data are normalized to maximum displacement of [ that male sexual behaviors are inhibited by exposure to acute stress (30) and that this stress-induced inhibition of sexual behaviors is linked to both corticosterone and the opioid system. When male newts are exposed to acute stress, the incidence of amplectic clasping decreases in control animals, but not in males pretreated with metyrapone (the steroid synthesis inhibitor) (30) or naloxone (39). Furthermore, males injected with corticosterone or the -selective agonist BRE exhibit a rapid and pronounced inhibition of male sexual behaviors (30, 39).
Stress-induced increase in locomotor activity is another behavioral response in T. granulosa that has been linked to both corticosterone and opioid system. When male newts are exposed to acute stress, locomotor activity is enhanced in control animals, a response that is controlled by CRH acting centrally (45, 46) . This stress-induced increase in locomotor activity can be rapidly suppressed by an injection of corticosterone (43) or the -selective agonist BRE (44) . Therefore, as with stress-induced inhibition of sexual behaviors, corticosteroids and -selective agonists exert similar effects on locomotor activity.
There also are consistencies in the physiological functions of corticosteroids and the opioid system, which adds indirect support for our working hypothesis. First, one important physiological function for both corticosteroids and opioid receptors is to decrease ACTH activity by suppressing secretions of CRH and vasopression (VP) (57) (58) (59) (60) (61) . Second, dynorphin, the endogenous -selective neuropeptide, is colocalized in CRH-and VP-containing neurons (62) (63) (64) (65) . Third, opioid receptors have been found on presynaptic membranes of VP-containing neurons (66) and the activation of presynaptic opioid receptors inhibits VP secretion (67) . Likewise, corticosteroids have been shown to inhibit VP secretion (68) . This convergence in the effects of corticosteroids and opioid agonists on VP and CRH secretion may help to explain the behavioral responses in T. granulosa described above. In T. granulosa, male sexual behaviors are enhanced by AVT (69) , and the stress-induced increase in locomotor activity is enhanced by CRH (46) . Therefore, the inhibition of release of these two peptides (AVT and CRH) by corticosterone binding to and activating a specific opioid-like receptor could provide a mechanism by which corticosteroids rapidly inhibit sexual behaviors and locomotor activity. Figure 4 illustrates a model to summarize this hypothesis.
In summary, the main conclusion from the current study is that a subset of -selective ligands inhibit [
3 H]CORT binding in neuronal membranes from T. granulosa. These findings, when considered in conjunction with information about the inhibitory effects of corticosteroids and agonists on VP and CRH secretion and with the results from our behavioral studies in newts, are consistent with the hypothesis that the 
